期刊文献+

聚乳酸/乙醇酸复合bFGF降解支架在心肌血运重建中的应用实验 被引量:3

Experimental studies of degradable PLGA stent with basic fibroblast growth factor in myocardial revascularization
下载PDF
导出
摘要 目的探讨高分子缓释降解材料聚乳酸/乙醇酸(poly D,L-lactic/glycolic acid,PLGA)联合碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF),对心肌缺血区域灌注改善的情况。方法成功建立小型猪急性心肌梗死模型后随机分至空白对照组、PLGA支架对照组和PLGA复合bFGF支架组;6周后,SPECT结合软件EmoryCardiac Toolbox分析灌注缺损区域质量百分率的变化,超声学指标LVEDD、LVEDS、FS%评价心脏功能,Image ProPlus软件量化各组新生血管密度。结果6周后PLGA复合bFGF支架组新生血管密度、心肌灌注质量缺损百分率与空白对照组、PLGA支架对照组有显著差异(P<0.01),PLGA复合bFGF支架组FS%较空白对照组、PLGA支架对照组显著改善(P<0.05)。结论bFGF联合PLGA缓释材料能够显著增加新生血管密度,改善缺血部位心肌血流灌注,进而提高心脏功能。 AIM To investigate the effects of degradable poly D, L-lactic/glycolic acid (PLGA) with basic fibroblast growth factor (bFGF) on promoting myocardial revascularization. METHODS Miniswines with acute myocardial infarction were randomly assigned to control group, blank PLGA stent group and PLGA stent with bFGF group. Six weeks postoperatively, quantitative analysis of new vessels was performed by Image Pro Plus software. The mass defect percent of myocardial perfusion was calculated by Emory Cardiac Toolbox software. LVEDd, LVEDs and FS% reflective of cardiac function were meas- ured by echocardiology. RESULTS Six weeks postoperatively, both new vessels density and mass defect percent in PLGA stent with bFGF group showed significant difference compared with those in control group and blank PLGA stent group (P 〈0. O1 ). FS% in PLGA stent with bFGF group was significantly enhanced compared with that in the other two groups (P 〈 0. 05). CONCLUSION bFGF combined with degradable PLGA stent increases new vessel's density, improves myocardial perfusion and enhances cardiac function.
出处 《心脏杂志》 CAS 2009年第3期383-386,共4页 Chinese Heart Journal
基金 天津市科技发展计划项目资助(05YFGZSF02900)
关键词 心肌梗死 缓释 生长因子 量化分析 myocardial infarction growth factor slow release quantitative analysis
  • 相关文献

参考文献9

  • 1Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? [J]. Am J Cardiol, 1999, 84(5) :598 -600,A8.
  • 2刘莹,孙立军,宦怡,赵海涛,邓敬兰.bFGF促进缺血心肌血管生成和改善心肌功能的实验研究[J].心脏杂志,2006,18(3):280-283. 被引量:3
  • 3Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamic of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution[ J]. Cardiovasc Res, 1997, 36 ( 1 ) :78 - 85.
  • 4Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial isehemia[J]. J Pharmacol Exp Ther, 2000, 292(2) :795 - 802.
  • 5Teng CJ, Luo J, Chiu RC, et al. Mssive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty [ J ]. J Thorac Cardiovasc Surg, 2006, 132(3) :628 -632.
  • 6Chu VF, Giaid A, Kuang JQ, et al. Angiogenesis in transmyocardial revascularization: comparison of laser versus mechanical punctures[J]. Ann Thorac Surg, 1999, 68(2) :301 -307.
  • 7Horvath KA, Belkind N, Wu I, et al. Functional comparison of transmyocardial revascularization by mechanical and laser means [J]. Ann Thorac Surg, 2001, 72(6) :1997 -2002.
  • 8Krabatsch T, Tambeur L, Lieback E, et al. Transmyocardial laser revascularization in the treatment of end-stage coronary artery disease [J]. Ann Thorac Cardiovasc Surg, 1998, 4(2) :64 -71.
  • 9Gassler N, Wintzer HO, Stubbe HM, et al. Transmyocardial laser revascularization histological features in human nonresponder myocardium [ J ]. Circulation, 1997, 95 ( 2 ) :371 - 375.

二级参考文献13

  • 1Azrin M. Angiogenesis, protein and gene delivery[J]. Br Med Bull,2001,59(1):211-225.
  • 2Tomanek RJ, Zheng W, Yue X. Growth factor activation in myocardial vascularization: therapeutic implications[J]. Mol Cell Biochem,2004,264(1-2):3-11,35-44.
  • 3Iwakura A, Fujita M, Kataoka K, et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model[J]. Heart Vessels,2003,18(2):93 -99.
  • 4Lopez JJ, Edelman ER, Stamler A, et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia [J]. Am J Physiol, 1998,274 (3 Pt 2): H930-H936.
  • 5Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis) [J]. J Pathol,2000,190(3):338-342.
  • 6Fukuda S, Yoshii S, Kaga S, et al. Angiogenic strategy for human ischemic heart disease : brief overview [J]. Mol Cell Biochem,2004,264(1-2):143-149.
  • 7Nugent MA, lozzo RV. Fibroblast growth factor-2 [J]. Int J Biochem Cell Biol,2000,32 (2): 115-120.
  • 8Yanagisawa-miwa A, Uchida Y, Nakamum F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor[J]. Science, 1992,257(5075): 1401-1403.
  • 9Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model [J]. Am J Physiol, 1994,266(4 Pt 2):H1588-H1595.
  • 10Shou M, Thirumurti V, Rajanayagam S, et al. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels [J]. J Am Coll Cardiol, 1997,29(5): 1102 -1106.

共引文献2

同被引文献34

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部